Mutanome Engineered RNA Immunotherapy: Towards Patient-Centered Tumor Vaccination
Advances in nucleic acid sequencing technologies have revolutionized the field of genomics, allowing the efficient targeting of mutated neoantigens for personalized cancer vaccination. Due to their absence during negative selection of T cells and their lack of expression in healthy tissue, tumor mut...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2015-01-01
|
| Series: | Journal of Immunology Research |
| Online Access: | http://dx.doi.org/10.1155/2015/595363 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832545879348740096 |
|---|---|
| author | Mathias Vormehr Barbara Schrörs Sebastian Boegel Martin Löwer Özlem Türeci Ugur Sahin |
| author_facet | Mathias Vormehr Barbara Schrörs Sebastian Boegel Martin Löwer Özlem Türeci Ugur Sahin |
| author_sort | Mathias Vormehr |
| collection | DOAJ |
| description | Advances in nucleic acid sequencing technologies have revolutionized the field of genomics, allowing the efficient targeting of mutated neoantigens for personalized cancer vaccination. Due to their absence during negative selection of T cells and their lack of expression in healthy tissue, tumor mutations are considered as optimal targets for cancer immunotherapy. Preclinical and early clinical data suggest that synthetic mRNA can serve as potent drug format allowing the cost efficient production of highly efficient vaccines in a timely manner. In this review, we describe a process, which integrates next generation sequencing based cancer mutanome mapping, in silico target selection and prioritization approaches, and mRNA vaccine manufacturing and delivery into a process we refer to as MERIT (mutanome engineered RNA immunotherapy). |
| format | Article |
| id | doaj-art-c6c3ffbc1cb248df9d416c06614928f5 |
| institution | Kabale University |
| issn | 2314-8861 2314-7156 |
| language | English |
| publishDate | 2015-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Immunology Research |
| spelling | doaj-art-c6c3ffbc1cb248df9d416c06614928f52025-02-03T07:24:30ZengWileyJournal of Immunology Research2314-88612314-71562015-01-01201510.1155/2015/595363595363Mutanome Engineered RNA Immunotherapy: Towards Patient-Centered Tumor VaccinationMathias Vormehr0Barbara Schrörs1Sebastian Boegel2Martin Löwer3Özlem Türeci4Ugur Sahin5Research Center for Immunotherapy (FZI), Langenbeckstr. 1, Building 708, 55131 Mainz, GermanyTRON-Translational Oncology at the University Medical Center of Johannes Gutenberg University, Freiligrathstr. 12, 55131 Mainz, GermanyTRON-Translational Oncology at the University Medical Center of Johannes Gutenberg University, Freiligrathstr. 12, 55131 Mainz, GermanyTRON-Translational Oncology at the University Medical Center of Johannes Gutenberg University, Freiligrathstr. 12, 55131 Mainz, GermanyTRON-Translational Oncology at the University Medical Center of Johannes Gutenberg University, Freiligrathstr. 12, 55131 Mainz, GermanyResearch Center for Immunotherapy (FZI), Langenbeckstr. 1, Building 708, 55131 Mainz, GermanyAdvances in nucleic acid sequencing technologies have revolutionized the field of genomics, allowing the efficient targeting of mutated neoantigens for personalized cancer vaccination. Due to their absence during negative selection of T cells and their lack of expression in healthy tissue, tumor mutations are considered as optimal targets for cancer immunotherapy. Preclinical and early clinical data suggest that synthetic mRNA can serve as potent drug format allowing the cost efficient production of highly efficient vaccines in a timely manner. In this review, we describe a process, which integrates next generation sequencing based cancer mutanome mapping, in silico target selection and prioritization approaches, and mRNA vaccine manufacturing and delivery into a process we refer to as MERIT (mutanome engineered RNA immunotherapy).http://dx.doi.org/10.1155/2015/595363 |
| spellingShingle | Mathias Vormehr Barbara Schrörs Sebastian Boegel Martin Löwer Özlem Türeci Ugur Sahin Mutanome Engineered RNA Immunotherapy: Towards Patient-Centered Tumor Vaccination Journal of Immunology Research |
| title | Mutanome Engineered RNA Immunotherapy: Towards Patient-Centered Tumor Vaccination |
| title_full | Mutanome Engineered RNA Immunotherapy: Towards Patient-Centered Tumor Vaccination |
| title_fullStr | Mutanome Engineered RNA Immunotherapy: Towards Patient-Centered Tumor Vaccination |
| title_full_unstemmed | Mutanome Engineered RNA Immunotherapy: Towards Patient-Centered Tumor Vaccination |
| title_short | Mutanome Engineered RNA Immunotherapy: Towards Patient-Centered Tumor Vaccination |
| title_sort | mutanome engineered rna immunotherapy towards patient centered tumor vaccination |
| url | http://dx.doi.org/10.1155/2015/595363 |
| work_keys_str_mv | AT mathiasvormehr mutanomeengineeredrnaimmunotherapytowardspatientcenteredtumorvaccination AT barbaraschrors mutanomeengineeredrnaimmunotherapytowardspatientcenteredtumorvaccination AT sebastianboegel mutanomeengineeredrnaimmunotherapytowardspatientcenteredtumorvaccination AT martinlower mutanomeengineeredrnaimmunotherapytowardspatientcenteredtumorvaccination AT ozlemtureci mutanomeengineeredrnaimmunotherapytowardspatientcenteredtumorvaccination AT ugursahin mutanomeengineeredrnaimmunotherapytowardspatientcenteredtumorvaccination |